Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

Ionis on Monday revealed new six-month data from its Angelman syndrome program, presenting Phase 1/2a results from a pooled group of patients taking three different …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ASH 2024 discussions shine spotlight on advances in haemophilia treatments – Pharmaceutical Technology

Representative image to depict Hemophilia World Day. Image credit: Getty Images/ AndreyPopov At the American Society of Hematology (ASH) Annual Meeting 2024, physicians looked back

December 11, 2024

Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis

Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development strategies.

November 14, 2024

Senators tussle over abortion policy against the backdrop of a presidential campaign

But in the hearing room Tuesday, Republicans accused Democrats of “fear-mongering” over restrictive laws and pointed to states’ exceptions to save the life of the

June 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.